TABLE 2.

Levels of C5DC in the blood, C5DC/C8 ratios and urinary GA in each of the three groups.

	C5DC (μmol/L)		C5DC/C8		GA (mmol/mol Cr)
Reference range	0.02∼0.25		0.10∼2.50		0∼8
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
All patients	0.92 (0.11∼5.13)	0.86 (0.06∼4.68)	22.04 (1.6∼218)	11.86 (0.46∼73.45)	562.76 (0.12∼4,514)	201 (0.96∼1,099)
NBS patients	1.64 (0.11∼3.2)	1.77 (0.75∼4.68)	19.81 (1.6∼214)	12.54 (2.71∼40.57)	547.51 (1.92∼2,477)	230.85 (45.59∼378.82)
Clinical patients	0.83 (0.13∼5.13)	0.60 (0.06∼4.49)	22.29 (2.58∼218)	11.712 (0.46∼73.45)	578 (0.12∼4,514)	157.7 (0.96∼1,099)
P(NBS–Clinical)	0.148	0.002	0.973	0.657	0.947	0.702
P(all patients)*	0.012		<0.001		<0.001
P(NBS)*	0.477		0.011		0.012
P(Clinical)*	0.014		<0.001		<0.001

^∗P value for each group before and after treatment.

NBS, newborn screening.